Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.029
Neutral
RSI(14)
41.167
Neutral
STOCH(KDJ)(9,3,3)
17.090
Neutral
ATR(14)
0.154
High Vlolatility
CCI(14)
-79.447
Neutral
Williams %R
79.621
Sell
TRIX(12,20)
-1.082
Sell
StochRSI(14)
59.222
Buy
Jaguar Health Inc
JAGX1.130USD
+0.040+3.67%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
4.17MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Jaguar Health Inc
Currency: USD Updated: 2025-12-24Key Insights
Jaguar Health Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 107/158 in the Pharmaceuticals industry.Institutional ownership is high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 16.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Jaguar Health Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
16.000
Target Price
+1354.55%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Jaguar Health Inc Highlights
StrengthsRisks
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
Growing
The company is in a growing phase, with the latest annual income totaling USD 11.69M.
Overvalued
The company’s latest PE is -0.00, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 13.70K shares, decreasing 86.54% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.64K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-24The current financial score of Jaguar Health Inc is 7.01, ranking 132/158 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 3.08M, representing a year-over-year decrease of 0.80%, while its net profit experienced a year-over-year decrease of 3.57%.
Score
Financials
4.05
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.10
Operational Efficiency
10.00
Growth Potential
6.71
Shareholder Returns
7.19
Jaguar Health Inc's Company Valuation
Currency: USD Updated: 2025-12-24The current valuation score of Jaguar Health Inc is 7.22, ranking 90/158 in the Pharmaceuticals industry. Its current P/E ratio is -0.00, which is -224500.00% below the recent high of 0.90 and -65225.00% above the recent low of -0.26.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 107/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-24The current earnings forecast score of Jaguar Health Inc is 10.00, ranking 1/158 in the Pharmaceuticals industry. The average price target for Jaguar Health Inc is 16.00, with a high of 16.00 and a low of 16.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
16.000
Target Price
+1354.55%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Jaguar Health Inc
JAGX
1
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-24The current price momentum score of Jaguar Health Inc is 1.06, ranking 158/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.42 and the support level at 0.92, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.142
Sell
MA10
1.212
Sell
MA20
1.194
Sell
MA50
1.555
Sell
MA100
1.787
Sell
MA200
3.467
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-24The current institutional shareholding score of Jaguar Health Inc is 3.00, ranking 92/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 0.68%, representing a quarter-over-quarter decrease of 94.78%. The largest institutional shareholder is The Vanguard, holding a total of 1.64K shares, representing 0.04% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2025-12-24The current risk assessment score of Jaguar Health Inc is 2.20, ranking 132/158 in the Pharmaceuticals industry. The company's beta value is -0.42. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
-0.42
VaR
+10.78%
240-Day Maximum Drawdown
+96.04%
240-Day Volatility
+133.38%
Return
Best Daily Return
60 days
+13.68%
120 days
+13.68%
5 years
--
Worst Daily Return
60 days
-18.67%
120 days
-20.08%
5 years
-100.00%
Sharpe Ratio
60 days
-2.08
120 days
-1.40
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+96.04%
3 years
+99.98%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
-0.99
3 years
-0.33
5 years
-0.20
Skewness
240 days
--
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
+133.38%
5 years
+151.89%
Standardised True Range
240 days
+61.86%
5 years
+587880.34%
Downside Risk-Adjusted Return
120 days
-191.70%
240 days
-191.70%
Maximum Daily Upside Volatility
60 days
+81.37%
Maximum Daily Downside Volatility
60 days
+76.00%
Liquidity
Average Turnover Rate
60 days
+16.33%
120 days
+35.49%
5 years
--
Turnover Deviation
20 days
-99.89%
60 days
-99.92%
120 days
-99.82%
Peer Comparison
Pharmaceuticals
Jaguar Health Inc
JAGX
5.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.78 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Jaguar Health Inc?
The TradingKey Stock Score provides a comprehensive assessment of Jaguar Health Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Jaguar Health Inc’s performance and outlook.
How do we generate the financial health score of Jaguar Health Inc?
To generate the financial health score of Jaguar Health Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Jaguar Health Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Jaguar Health Inc.
How do we generate the company valuation score of Jaguar Health Inc?
To generate the company valuation score of Jaguar Health Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Jaguar Health Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Jaguar Health Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Jaguar Health Inc.
How do we generate the earnings forecast score of Jaguar Health Inc?
To calculate the earnings forecast score of Jaguar Health Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Jaguar Health Inc’s future.
How do we generate the price momentum score of Jaguar Health Inc?
When generating the price momentum score for Jaguar Health Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Jaguar Health Inc’s prices. A higher score indicates a more stable short-term price trend for Jaguar Health Inc.
How do we generate the institutional confidence score of Jaguar Health Inc?
To generate the institutional confidence score of Jaguar Health Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Jaguar Health Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Jaguar Health Inc.
How do we generate the risk management score of Jaguar Health Inc?
To assess the risk management score of Jaguar Health Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Jaguar Health Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Jaguar Health Inc.
